Lv4
650 积分 2023-08-04 加入
A novel angiogenesis-related scoring model predicts prognosis risk and treatment responsiveness in diffuse large B-cell lymphoma
1个月前
已完结
Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist
1个月前
已完结
Population Pharmacokinetics of siRNA JNJ-73763989 in Healthy Participants and Patients With Chronic Hepatitis B
2个月前
已完结
Multicentre gene therapy for OTOF-related deafness followed up to 2.5 years
2个月前
已完结
Noninvasive surrogate endpoints of adverse outcomes, disease progression, and treatment efficacy in Metabolic Dysfunction–Associated Steatohepatitis (MASH)
4个月前
已关闭
Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B
8个月前
已完结
Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
10个月前
已关闭
A Double‐Blind, Placebo‐Controlled, Single‐Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT‐101, an RNAi Therapeutic Targeting HBV Infection
1年前
已完结
Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: a randomized, double-blind, placebo-controlled study
1年前
已完结
First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects
1年前
已完结
皖公网安备34019202002308
